{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-115985","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.100886+00:00","generated_at":"2026-06-08T06:26:16.671266+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Ironwood Q3 total revenue $113.7M, GAAP diluted EPS $0.09 vs $0.28 YoY","bullets":["Total revenues $113.7M (up 5% YoY); GAAP net income $15.3M, diluted EPS $0.09 vs $0.28.","LINZESS U.S. net sales $279M (+7% YoY); prescription demand +8%.","Positive final data from Phase II STARS Nutrition study of apraglutide in SBS-IF with CIC.","Expects topline data for CNP-104 in primary biliary cholangitis in Q3 2024.","Maintains full year 2023 guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-115985","json":"https://secwatch.observer/filing/0001104659-23-115985.json","markdown":"https://secwatch.observer/filing/0001104659-23-115985.md","text":"https://secwatch.observer/filing/0001104659-23-115985.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923115985/0001104659-23-115985-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923115985/tm2330146d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:26:16.671266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c17e974f3edb86a5421f9986128f2eb37c316cb9","claim":"IRONWOOD PHARMACEUTICALS INC reported the quarter ended September 30, 2023 results: revenue Total revenues $ 113,739 $ 108,637, net income GAAP net income 13,950 50,317, EPS GAAP net income attributable to Ironwood Pharmaceuticals, Inc. per share – diluted 0.09 0.28. Guidance reaffirmed.","evidence_excerpt":"the year and meaningful pipeline catalysts ahead in 2024.” Third Quarter 2023 Financial Highlights 1 (in thousands, except for per share amounts) Q3 2023 Q3 2022 Total revenues $ 113,739 $ 108,637 Total operating expenses 73,716 40,164 GAAP net income 13,950 50,317 GAAP net income attributable to Ironwood Pharmaceuticals, Inc. 15,321 50,317 GAAP net income","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923115985/0001104659-23-115985-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"Total revenues $ 113,739 $ 108,637"},{"label":"Net income","value":"GAAP net income 13,950 50,317"},{"label":"EPS","value":"GAAP net income attributable to Ironwood Pharmaceuticals, Inc. per share – diluted 0.09 0.28"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}